EA022354B9 - Терапевтическое применение конъюгатов интерферон-пэг - Google Patents

Терапевтическое применение конъюгатов интерферон-пэг

Info

Publication number
EA022354B9
EA022354B9 EA201200865A EA201200865A EA022354B9 EA 022354 B9 EA022354 B9 EA 022354B9 EA 201200865 A EA201200865 A EA 201200865A EA 201200865 A EA201200865 A EA 201200865A EA 022354 B9 EA022354 B9 EA 022354B9
Authority
EA
Eurasian Patent Office
Prior art keywords
interferon
therapeutic use
peg conjugates
conjugates
peg
Prior art date
Application number
EA201200865A
Other languages
English (en)
Other versions
EA201200865A1 (ru
EA022354B1 (ru
Inventor
Ко-Чун Линь
Рудольф Др. Видманн
Original Assignee
Фармаэссентия Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармаэссентия Корпорейшн filed Critical Фармаэссентия Корпорейшн
Publication of EA201200865A1 publication Critical patent/EA201200865A1/ru
Publication of EA022354B1 publication Critical patent/EA022354B1/ru
Publication of EA022354B9 publication Critical patent/EA022354B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение имеет отношение к применению конъюгатов интерферона с полимером, описанных в подробном описании, для лечения идиопатического миелофиброза, истинной полицитемии и идиопатической тромбоцитемии.
EA201200865A 2009-12-10 2010-12-09 Терапевтическое применение конъюгатов интерферон-пэг EA022354B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28541109P 2009-12-10 2009-12-10
PCT/US2010/059714 WO2011072138A2 (en) 2009-12-10 2010-12-09 Therapeutic use of protein-polymer conjugates

Publications (3)

Publication Number Publication Date
EA201200865A1 EA201200865A1 (ru) 2012-11-30
EA022354B1 EA022354B1 (ru) 2015-12-30
EA022354B9 true EA022354B9 (ru) 2016-02-29

Family

ID=44146181

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200865A EA022354B9 (ru) 2009-12-10 2010-12-09 Терапевтическое применение конъюгатов интерферон-пэг

Country Status (32)

Country Link
US (1) US8617532B2 (ru)
EP (1) EP2509593B1 (ru)
JP (1) JP5547816B2 (ru)
KR (1) KR101782084B1 (ru)
CN (1) CN102724980B (ru)
AR (1) AR079369A1 (ru)
AU (1) AU2010328067B2 (ru)
BR (1) BR112012014017B1 (ru)
CA (1) CA2782624C (ru)
CL (1) CL2012001503A1 (ru)
CY (1) CY1122901T1 (ru)
DK (1) DK2509593T3 (ru)
EA (1) EA022354B9 (ru)
ES (1) ES2786025T3 (ru)
HK (1) HK1176015A1 (ru)
HR (1) HRP20200678T1 (ru)
HU (1) HUE049051T2 (ru)
IL (1) IL220249A0 (ru)
LT (1) LT2509593T (ru)
MA (1) MA33913B1 (ru)
MX (1) MX337705B (ru)
MY (1) MY169961A (ru)
NZ (1) NZ600528A (ru)
PL (1) PL2509593T3 (ru)
PT (1) PT2509593T (ru)
RS (1) RS60336B1 (ru)
SG (1) SG181084A1 (ru)
SI (1) SI2509593T1 (ru)
TN (1) TN2012000256A1 (ru)
UA (1) UA109646C2 (ru)
WO (1) WO2011072138A2 (ru)
ZA (1) ZA201205056B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017005244A (es) * 2014-11-06 2017-08-18 Pharmaessentia Corp Regimen de dosificacion para interferon pegilado.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060166932A1 (en) * 2002-11-06 2006-07-27 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
WO2009023826A1 (en) * 2007-08-16 2009-02-19 Pharmaessentia Corp. Protein-polymer conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028163T2 (en) * 2002-01-18 2016-11-28 Biogen Ma Inc Polyalkylene polymer compounds and their use
CN101636414B (zh) * 2007-09-04 2012-02-15 厦门伯赛基因转录技术有限公司 聚乙二醇修饰的干扰素α2b及其制备方法和应用
GB0908393D0 (en) * 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060166932A1 (en) * 2002-11-06 2006-07-27 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
WO2009023826A1 (en) * 2007-08-16 2009-02-19 Pharmaessentia Corp. Protein-polymer conjugates

Also Published As

Publication number Publication date
CA2782624C (en) 2016-11-01
KR101782084B1 (ko) 2017-09-26
EA201200865A1 (ru) 2012-11-30
HK1176015A1 (en) 2013-07-19
MX2012006132A (es) 2012-06-19
TN2012000256A1 (en) 2013-12-12
CN102724980B (zh) 2014-10-15
JP2013513611A (ja) 2013-04-22
BR112012014017A2 (pt) 2016-04-12
HRP20200678T1 (hr) 2020-10-02
CN102724980A (zh) 2012-10-10
PT2509593T (pt) 2020-04-21
CL2012001503A1 (es) 2012-11-09
BR112012014017B1 (pt) 2021-10-26
AR079369A1 (es) 2012-01-18
LT2509593T (lt) 2020-05-25
KR20120110105A (ko) 2012-10-09
ZA201205056B (en) 2013-03-27
IL220249A0 (en) 2012-07-31
RS60336B1 (sr) 2020-07-31
EP2509593A4 (en) 2016-01-13
WO2011072138A9 (en) 2011-10-06
EA022354B1 (ru) 2015-12-30
MA33913B1 (fr) 2013-01-02
EP2509593B1 (en) 2020-02-12
MY169961A (en) 2019-06-19
AU2010328067B2 (en) 2014-10-02
UA109646C2 (uk) 2015-09-25
SI2509593T1 (sl) 2020-07-31
MX337705B (es) 2016-03-15
SG181084A1 (en) 2012-07-30
PL2509593T3 (pl) 2020-08-24
CA2782624A1 (en) 2011-06-16
AU2010328067A1 (en) 2012-07-05
US8617532B2 (en) 2013-12-31
JP5547816B2 (ja) 2014-07-16
CY1122901T1 (el) 2021-05-05
ES2786025T3 (es) 2020-10-08
NZ600528A (en) 2014-01-31
WO2011072138A2 (en) 2011-06-16
HUE049051T2 (hu) 2020-09-28
EP2509593A2 (en) 2012-10-17
DK2509593T3 (da) 2020-05-11
US20110262380A1 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
HK1216880A1 (zh) 某些三唑並吡啶化合物、其組合物和它們在治療癌症中的用途
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
MY158992A (en) Forms of rifaximin and uses thereof
EA201101522A1 (ru) Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10)
EA201171367A1 (ru) Винилиндазолильные соединения
MX355543B (es) Macrociclos peptidomiméticos.
MX2011007930A (es) Conjugados de insulina cristalina.
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
SG10201408166QA (en) Probiotic microorganisms as active agents for enhancing the radiance of the skin’s complexion
AP2011005672A0 (en) Pyrazolopyrimidines and their use for the treatment of CNS disorders.
MX350234B (es) Compuestos de enlace especificos de bacterias gram-positivas.
EP2425001A4 (en) ANTI-HIV COMBINATION VECTORS, TARGETING VECTORS AND METHOD OF USE
AU331187S (en) Massage device
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
EA201270264A1 (ru) Лечение метастазов в головной мозг ингибиторами рецепторов эндотелина в комбинации с цитотоксическим химиотерапевтическим средством
WO2010132370A3 (en) Soluble tlt-1 for the treatment and diagnosis of sepsis
EP2766051A4 (en) PORPHYRINE-PHOSPHOLIPID CONJUGATE MICROBULLES AND THEIR USE AS CONTRAST AGENTS
EP2576575A4 (en) PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF
MX2010010873A (es) Uso de una combinacion de udenafil y alfuzosin u oxibutinina para el tratamiento de la vejiga hiperactiva.
CL2011002967A1 (es) Compuestos derivados de 3-oxadiazolil-5-fenil-piperidina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamient y/o profilaxis de trastornos cardiovasculares, tromboembolicos y tumorales.
EP2247730A4 (en) SPECIMEN SPIDER TOXIN PHONEUTRIA NIGRIVENTER FOR THE TREATMENT OF ERECTILE DYSFUNCTION
EA022354B9 (ru) Терапевтическое применение конъюгатов интерферон-пэг
MX2012001144A (es) Compuestos para el tratamiento de inflamacion.
MX2013006184A (es) Compuestos de oxazol [5, 4-b]piridin-5-ilo y su uso para el tratamiento de cancer.
SG178929A1 (en) Use of cathepsin h

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent